Secondary Logo

Journal Logo

Damage Control Resuscitation: Directly Addressing the Early Coagulopathy of Trauma

Holcomb, John B. MD, FACS; Jenkins, Don MD, FACS; Rhee, Peter MD, FACS; Johannigman, Jay MD, FS, FACS; Mahoney, Peter FRCA, RAMC; Mehta, Sumeru MD; Cox, E Darrin MD, FACS; Gehrke, Michael J. MD; Beilman, Greg J. MD, FACS; Schreiber, Martin MD, FACS; Flaherty, Stephen F. MD, FACS; Grathwohl, Kurt W. MD; Spinella, Phillip C. MD; Perkins, Jeremy G. MD; Beekley, Alec C. MD, FACS; McMullin, Neil R. MD; Park, Myung S. MD, FACS; Gonzalez, Ernest A. MD, FACS; Wade, Charles E. PhD; Dubick, Michael A. PhD; Schwab, C William MD, FACS; Moore, Fred A. MD, FACS; Champion, Howard R. FRCS; Hoyt, David B. MD, FACS; Hess, John R. MD, MPH, FACP

The Journal of Trauma: Injury, Infection, and Critical Care: February 2007 - Volume 62 - Issue 2 - p 307-310
doi: 10.1097/TA.0b013e3180324124
Special Commentary
Free

From the USAISR (J.B.H.), Fort Sam Houston, TX; CENTCOM Trauma (D.J.), Camp Victory, Iraq; Navy Trauma Training Center (P.R.), Los Angeles, CA; 332nd Expeditionary Medical Group (J.J.), Balad Air Base, Iraq; ADMEM RCDM (P.M.), Birmingham, United Kingdom; Emergency Department (S.M.), 10th Combat Support Hospital, Baghdad, Iraq; Department of Surgery (E.D.C.), 10th Combat Support Hospital, Baghdad, Iraq; Chief of Anesthesia (M.J.G.), 10th Combat Support Hospital, Baghdad, Iraq.

Submitted for publication September 22, 2006.

Accepted for publication December 20, 2006.

Address for reprints: COL John B. Holcomb, MD, FACS, Trauma Consultant for the Surgeon General, Commander, US Army Institute of Surgical Research, 3400 Rawley E. Chambers Avenue, Fort Sam Houston, TX 78234-6315; email: john.holcomb@amedd.army.mil.

Rapid progress in trauma care occurs when the results of translational research are promptly integrated into clinical practice. Experience with a high volume of severely injured casualties expedites the process.1 Historically, these conditions have converged during times of conflict, improving the care of combat casualties and subsequently that of civilian trauma patients.1,2

In the most severely injured casualties, we know that when the lethal triad of hypothermia, acidosis, and coagulopathy are present, death is imminent.3 Current teaching is to avoid reaching these conditions by using “damage control surgery.”4–6 However, conventional resuscitation practice for damage control focuses on rapid reversal of acidosis and prevention of hypothermia, and surgical techniques focus on controlling hemorrhage and contamination. Direct treatment of coagulopathy has been relatively neglected, viewed as a byproduct of resuscitation, hemodilution, and hypothermia, and delayed by blood banking logistics. Damage control resuscitation addresses the entire lethal triad immediately upon admission to a combat hospital.7,8

By demonstrating that in the severely injured the coagulopathy of trauma is present at admission, recent studies have brought back to light the importance of treating this disorder at an earlier stage.9–12 Reports of lactated Ringer's solution and normal saline increasing reperfusion injury and leukocyte adhesion lead one to conclude that the standard crystalloid-based resuscitation guidelines in prehospital trauma life support (PHTLS) and advanced trauma life support (ATLS) may worsen the presenting acidosis and coagulopathy in severely injured trauma patients, and possibly increase ARDS, SIRS, and MOF.13–17 The safety of withholding PRBCs in hemodynamically stable patients has been demonstrated,18 and the risks associated with blood transfusion are well described.19,20 Further, massive transfusion in military and civilian casualties has been associated with an increased risk of death.21–23 Taken together, these observations suggest that the most severely injured may need a resuscitative approach tailored specifically to their needs. However, even in the largest civilian academic trauma centers, patients with injuries at the outer limits of survivability, such as those massively transfused with more than 10 units of RBCs in the first 24 hours, are uncommon and constitute only 1% to 2% of the patient population, making it difficult to develop and test new resuscitation concepts.21 Because 7% of combat casualties require massive transfusion, we have had just such an opportunity to observe the effects of new resuscitation strategies in the combat hospitals of Iraq and Afghanistan.

The military munitions used in Southwest Asia can inflict severe multisystem injuries on both combatants and civilians. These patients frequently present to American military medical personnel shortly after being wounded. Unlike civilian systems, where treatment of coagulopathy is often limited by standard blood bank logistics, in Iraq we frequently have immediate access to PRBCs and thawed AB or A plasma, and rapid access to apheresis platelets, prepooled cryoprecipitate, fresh whole blood, and rFVIIa, as indicated.24–29 Thus, the opportunity to formally evaluate the immediate and direct treatment of the coagulopathy of trauma is available.

The trauma patients who are most severely injured (approximately 10%) also represent the majority of in-hospital trauma deaths. Considerable attention has been directed toward the technical details of damage control surgery and reversing the acidosis and hypothermia present at admission. Less attention has been directed toward reversing the coagulopathy related to blood loss that is present at the same time. Clinical experience in Operation Iraqi Freedom and Operation Enduring Freedom suggests that coagulopathy may be present at the time of admission before significant resuscitative fluid has been given, as a consequence of acidosis-induced coagulation factor dysfunction, coagulation factor consumption, and hypothermia-induced failure of platelet activation. Failure to recognize and immediately address the coagulopathy found in severely injured patients can be linked to several factors. Most studies of trauma-induced coagulopathy have measured the laboratory changes that happen in the OR or ICU after dilution with crystalloid and PRBCs, and have concluded that the coagulopathy could be fully explained by the resuscitation and/or hypothermia.30

The goal of shock resuscitation efforts in the past has been largely to support blood pressure and urine output and to reverse the metabolic derangements associated with the ischemia associated with acute blood loss.31,32 Although these goals are obviously important, the studies supporting this concept were based on controlled animal hemorrhage studies, and the results were not evaluated in randomized human trials.33–35 Additionally, the potential benefits of mitigating ischemia-induced reperfusion injury after standard crystalloid resuscitation were not fully recognized.14,36 Furthermore, recent resuscitation studies have overlooked the importance of an integrated and coherent prehospital, ED, OR, and ICU shock resuscitation plan that incorporates intravascular treatment of coagulopathy.32,37 Finally, the current generation of clinicians has been taught to not use plasma as a resuscitation fluid.38 We agree that current standard resuscitation methods are appropriate policy for the approximately 90% of trauma patients who are not in shock and are hypercoagulable after injury.39–42 However, for the approximately 10% of casualties who constitute the most seriously injured, are in shock and coagulopathic, and represent the potentially preventable hemorrhagic deaths, liquid plasma may be the optimal resuscitation fluid currently available.43–50

Based on (1) previous civilian clinical studies, (2) the recommendations of an international consensus conference on early massive transfusion for trauma,51 and (3) considerable experience in the current war, we think patients at high risk for coagulopathy can be readily identified at admission and prompt simultaneous treatment of hypothermia, acidosis, and coagulopathy initiated. Hypothermia, an independent factor for increased mortality in trauma patients, was an earlier focus for active prevention and treatment,52–54 but application of training and equipment recommendations of the Committee on Tactical Combat Casualty Care and the Joint Theater Trauma System has made it an uncommon finding.55 Acidosis significantly impairs the thrombin generation rates, critical to optimal coagulation function56 and is thus aggressively managed by use of THAM and volume loading with blood components once hemostasis is obtained, with restoration of a normal blood lactate, base deficit, or pH as the ultimate goal. Damage control resuscitation as a structured intervention begins immediately after rapid initial assessment in the ED and progresses through the OR into the ICU. All efforts are directed toward this goal by repeated point of care testing and the use of multiple blood products and drugs readily available in theater, albeit in new ratios and amounts. Compared with civilian practice, damage control resuscitation efforts are largely completed in the OR, with little resuscitation required in the ICU. Achieving this goal quickly in the OR may allow a shift from limited damage control surgery to earlier definitive surgical interventions, including sophisticated limb salvage techniques, and improved outcomes.

In the severely injured casualty, damage control resuscitation consists of two parts and is initiated within minutes of arrival in the ED. First, resuscitation is limited to keep blood pressure at approximately 90 mm Hg, preventing renewed bleeding from recently clotted vessels.15,17,39,57–62 Second, intravascular volume restoration is accomplished by using thawed plasma as a primary resuscitation fluid in at least a 1:1 or 1:2 ratio with PRBCs.8,10,48–50 Our initial clinical experience shows these ratios decrease mortality in similarly injured casualties (Borgman MA, et al. unpublished data). Recombinant FVIIa is occasionally used along with the early units of red cells and as required throughout the resuscitation. For casualties who will require continued resuscitation, the blood bank is notified to activate the massive transfusion protocol and deliver to the operating room 6 units of plasma, 6 units of PRBCs, 6 packs of platelets, and 10 units of cryoprecipitate stored in individual coolers.50 The most severely injured of this group also receive fresh warm whole blood as a resuscitative fluid.47,63 Additional coolers, containing the same mix of blood products, are provided as needed until the massive transfusion order is cancelled. Crystalloid use is minimized and serves mainly as a drug carrier and to keep lines open between the units of blood products.

In combat casualties requiring major resuscitation (10–40 units of blood products), we have found as little as 5 L to 8 L of crystalloid are utilized during the first 24 hours, representing a decrease of at least 50% when compared with current standard resuscitation practices. Using the damage control resuscitation approach, the lack of intraoperative coagulopathic bleeding has been remarkable, allowing surgeons to focus on surgical bleeding. Patients treated in this fashion almost always arrive in the ICU warm, euvolemic, and non-acidotic, with a normal INR and minimal edema. In the majority of patients the abnormalities of the lethal triad are absent. These patients appear to be easily ventilated and more quickly extubated than patients with similar blood loss treated with the standard crystalloid resuscitation volumes and blood component ratios. These admittedly anecdotal yet compelling observations cause us to question further the use of excessive crystalloid resuscitation and to begin to formulate hypotheses that can be tested to demonstrate beneficial effects of pre-emptive control of coagulopathy.14

For the first time in US warfare, data for all admitted trauma casualties in the current conflict in Southwest Asia are entered into a joint theater trauma registry (JTTR).64 A deployed combat research team is being sent into theater for the first time since Vietnam, operating under the same standards of IRB approval as practiced in the United States. Data collected by this team, along with outcome data from the JTTR, will allow an analysis of the effects of resuscitation with thawed plasma, fresh whole blood, administration of rFVIIa, and limited crystalloid. Additionally, focused effort will be required to describe the mechanisms causing the early coagulopathy of trauma present at admission. The clinical effects and consequences of damage control resuscitation will be measurable in patient outcomes. We will know if we are saving more severely injured soldiers, if reducing coagulopathy and edema leads to better outcomes, and, ultimately, whether we are creating more blood exposure or less. We will soon have sufficient data to assess the full benefits of damage control resuscitation in the population of critically injured for whom it matters most. As in the past, perceptive observation, thoughtful discussion, and insightful analysis concerning medical care during war from experienced military medics, surgeons, and scientists, in concert with our civilian colleagues, will generate recommendations for new and improved medical practice, with continuous modification as further experience, research, and development produce new and relevant information.1,2

Back to Top | Article Outline

REFERENCES

1. DeBakey ME. The torch that illuminates: lessons from military medicine. Mil Med. 1996;161:711–716.
2. Pruitt BA Jr. Combat casualty care and surgical progress. Ann Surg. 2006;243:715–729.
3. Moore EE, Thomas G. Orr Memorial Lecture. Staged laparotomy for the hypothermia, acidosis, and coagulopathy syndrome. Am J Surg. 1996;172:405–410.
4. Rotondo MF, Zonies DH. The damage control sequence and underlying logic. Surg Clin North Am. 1997;77:761–777.
5. Schwab CW. Introduction: damage control at the start of 21st century. Injury. 2004;35:639–641.
6. Holcomb JB, Helling TS, Hirshberg A. Military, civilian, and rural application of the damage control philosophy. Mil Med. 2001;168:490–493.
7. Hess JR, Holcomb JB, Hoyt DB. Damage control resuscitation: the need for specific blood products to treat the coagulopathy of trauma. Transfusion. 2006;46:685–686.
8. McMullin NR, Holcomb JB, Sondeen JL. Hemostatic resuscitation. In Vincent JL (ed.): Yearbook of Intensive Care and Emergency Medicine 2006. Berlin Heidelberg: Springer-Verlag; 2006: pp 265–278.
9. Brohi K, Singh J, Heron M, Coats T. Acute traumatic coagulopathy. J Trauma. 2003;54:1127–1130.
10. Hirshberg A, Dugas M, Banez EI, Scott BG, Wall MJ Jr, Mattox KL. Minimizing dilutional coagulopathy in exsanguinating hemorrhage: a computer simulation. J Trauma. 2003;54:454–463.
11. MacLeod JB, Lynn M, McKenney MG, Cohn SM, Murtha M. Early coagulopathy predicts mortality in trauma. J Trauma. 2003;55:39–44.
12. Faringer PD, Mullins RJ, Johnson RL, Trunkey DD. Blood component supplementation during massive transfusion of AS-1 red cells in trauma patients. J Trauma. 1993;34:481–487.
13. Coimbra R, Hoyt DB, Junger WG, et al. Hypertonic saline resuscitation decreases susceptibility to sepsis after hemorrhagic shock. J Trauma. 1997;42:602–606; discussion 606–607.
14. Cotton BA, Guy JS, Morris JA Jr, Abumrad NN. The cellular, metabolic, and systemic consequences of aggressive fluid resuscitation strategies. Shock. 2006;26:115–121.
15. Rhee P, Wang D, Ruff P, et al. Human neutrophil activation and increased adhesion by various resuscitation fluids. Crit Care Med. 2000;28:74–78.
16. Ayuste EC, Chen H, Koustova E, et al. Hepatic and pulmonary apoptosis after hemorrhagic shock in swine can be reduced through modifications of conventional Ringer's solution. J Trauma. 2006;60:52–63.
17. Rhee P, Koustova E, Alam HB. Searching for the optimal resuscitation method: recommendations for the initial fluid resuscitation of combat casualties. J Trauma. 2003;54(Suppl):S52–S62.
18. Hebert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion requirements in critical care investigators, Canadian critical care trials group. N Engl J Med. 1999;340:409–417.
19. Sheppard FR, Moore EE, Johnson JL, et al. Transfusion-induced leukocyte IL-8 gene expression is avoided by the use of human polymerized hemoglobin. J Trauma. 2004;57:720–725.
20. Malone DL, Dunne J, Tracy JK, et al. Blood transfusion, independent of shock severity, is associated with worse outcome in trauma. J Trauma. 2003;54:898–905; discussion 905–907.
21. Como JJ, Dutton RP, Scalea TM, Edelman BB, Hess JR. Blood transfusion rates in the care of acute trauma. Transfusion. 2004;44:809–813.
22. Eastridge BJ, Owsley J, Sebesta J, et al. Admission physiology criteria following injury on the battlefield predict medical resource utilization and patient mortality. J Trauma. 2006;61:820–823.
23. Hoyt DB. A clinical review of bleeding dilemmas in trauma. Semin Hematol. 2004;41(Suppl):40–43.
24. Boffard KD, Riou B, Warren B, et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma. 2005;59:8–18.
25. Jeroukhimov I, Jewelewicz D, Zaias J, et al. Early injection of high-dose recombinant factor VIIa decreases blood loss and prolongs time from injury to death in experimental liver injury. J Trauma. 2002;53:1053–1057.
26. Martinowitz U, Zaarur M, Yaron BL, Blumenfeld A, Martonovits G. Treating traumatic bleeding in a combat setting: possible role of recombinant activated factor VII. Mil Med. 2004;169(Suppl):16–18.
27. McMullin NR, Kauvar DS, Currier HM, et al. The clinical and laboratory response to recombinant factor VIIa in trauma and surgical patients with acquired coagulopathy. Curr Surg. 2006;63:246–251.
28. Mohr AM, Holcomb JB, Dutton RP, Duranteau J. Recombinant activated factor VIIa and hemostasis in critical care: a focus on trauma. Crit Care. 2005;9(Suppl):S37–S42.
29. Holcomb JB. Use of recombinant activated factor VII to treat the acquired coagulopathy of trauma. J Trauma. 2005;58:1298–1303.
30. Cosgriff N, Moore EE, Sauaia A, et al. Predicting life-threatening coagulopathy in the massively transfused patient: Hypothermia and acidosis revisited. J Trauma. 1997;42:857–862.
31. Davis JW, Parks SN, Kaups KL, Gladen HE, O'Donnell-Nicol S. Admission base deficit predicts transfusion requirements and risk of complications. J Trauma. 1996;41:769–774.
32. Moore FA, McKinley BA, Moore EE, et al. Inflammation and the host response to injury, a large-scale collaborative project: patient-oriented research core–standard operating procedures for clinical care. III. Guidelines for shock resuscitation. J Trauma. 2006;61:82–89.
33. Carrico CJ, Canizaro PC, Shires GT. Fluid resuscitation following injury: rationale for the use of balanced salt solutions. Crit Care Med. 1976;4:46–54.
34. Moore FD, Shires GT. Moderation. Anesth Analg. 1968;47:506–508.
35. McClelland RN, Shires GT, Baxter CR, Coln CD, Carrico CJ. Balanced salt solution in the treatment of hemorrhagic shock. JAMA. 1967;199:830–834.
36. Alam HB, Stanton K, Koustova E, et al. Effect of different resuscitation strategies on neutrophil activation in a swine model of hemorrhagic shock. Resuscitation. 2004;60:91–99.
37. Holcomb JB. Methods for improved hemorrhage control. Crit Care. 2004;8(Suppl):S57–S60.
38. Practice guidelines for perioperative blood transfusion and adjuvant therapies: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Transfusion and Adjuvant Therapies. Anesthesiology. 2006;105:198–208.
39. Burris D, Rhee P, Kaufmann C, et al. Controlled resuscitation for uncontrolled hemorrhagic shock. J Trauma. 1999;46:216–223.
40. Kiraly LN, Differding JA, Enomoto TM, et al. Resuscitation with normal saline (NS) vs. lactated ringers (LR) modulates hypercoagulability and leads to increased blood loss in uncontrolled hemorrhagic shock swine model. J Trauma. 2006;61:57–65.
41. Watts DD, Trask A, Soeken K, et al. Hypothermic coagulopathy in trauma: effect of varying levels of hypothermia on enzyme speed, platelet function, and fibrinolytic activity. J Trauma. 1998;44:846–854.
42. American College of Surgeons. Advanced Trauma Life Support. Chicago: American College of Surgeons, 1994.
43. Traverso LW, Hollenbach SJ, Bolin RB, Langford MJ, DeGuzman LR. Fluid resuscitation after an otherwise fatal hemorrhage: II. Colloid solutions. J Trauma. 1986;26:176–182.
44. Traverso LW, Lee WP, Langford MJ. Fluid resuscitation after an otherwise fatal hemorrhage: I. Crystalloid solutions. J Trauma. 1986;26:168–175.
45. Barbee RW, Kline JA, Watts JA. A comparison of resuscitation with packed red blood cells and whole blood following hemorrhagic shock in canines. Shock. 1999;12:449–453.
46. Mohr R, Goor DA, Yellin A, Moshkovitz Y, Shinfeld A, Martinowitz U. Fresh blood units contain large potent platelets that improve hemostasis after open heart operations. Ann Thorac Surg. 1992;53:650–654.
47. Repine TB, Perkins JG, Kauvar DS, Blackborne L. The use of fresh whole blood in massive transfusion. J Trauma. 2006;60(Suppl):S59–S69.
48. Ho AM, Dion PW, Cheng CA, et al. A mathematical model for fresh frozen plasma transfusion strategies during major trauma resuscitation with ongoing hemorrhage. Can J Surg. 2005;48:470–478.
49. Ketchum L, Hess JR, Hiippala S. Indications for early fresh frozen plasma, cryoprecipitate, and platelet transfusion in trauma. J Trauma. 2006;60(Suppl):S51–S8.
50. Malone DL, Hess JR, Fingerhut A. Massive transfusion practices around the globe and a suggestion for a common massive transfusion protocol. J Trauma. 2006;60(Suppl):S91–S6.
51. Holcomb JB, Hess JR. Early massive trauma transfusion: Current state of the art. J Trauma. 2006;60(Suppl):S1–S9.
52. Arthurs Z, Cuadrado D, Beekley A, et al. The impact of hypothermia on trauma care at the 31st combat support hospital. Am J Surg. 2006;191:610–614.
53. Gentilello LM, Jurkovich GJ, Stark MS, Hassantash SA, O'Keefe GE. Is hypothermia in the victim of major trauma protective or harmful? A randomized, prospective study. Ann Surg. 1997;226:439–447; discussion 447–449.
54. Martin RS, Kilgo PD, Miller PR, et al. Injury-associated hypothermia: an analysis of the 2004 National Trauma Data Bank. Shock. 2005;24:114–118.
55. Salomone JP, Pons PT, eds. PHTLS Basic and Advanced Prehospital Trauma Life Support: Military Edition. 6th ed. St. Louis: Mosby; 2006.
56. Martini WZ, Pusateri AE, Uscilowicz JM, Delgado AV, Holcomb JB. Independent contributions of hypothermia and acidosis to coagulopathy in swine. J Trauma. 2005;58:1002–1009; discussion 1009–1010.
57. Bickell WH, Wall MJ Jr, Pepe PE, et al. Immediate versus delayed fluid resuscitation for hypotensive patients with penetrating torso injuries. N Engl J Med. 1994;331:1105–1109.
58. Cannon WB, Fraser J, Cowell EM. The preventive treatment of wound shock. JAMA. 1918;70:618–621.
59. Dutton RP, Mackenzie CF, Scalea TM. Hypotensive resuscitation during active hemorrhage: impact on in-hospital mortality. J Trauma. 2002;52:1141–1146.
60. Holcomb JB. Fluid resuscitation in modern combat casualty care: lessons learned from Somalia. J Trauma. 2003;54(Suppl):S46–S51.
61. Sondeen JL, Coppes VG, Holcomb JB. Blood pressure at which rebleeding occurs after resuscitation in swine with aortic injury. J Trauma. 2003;54(Suppl):S110–S117.
62. Beecher HK. Preparation of battle casualties for surgery. Ann Surg. 1945;21:769–792.
63. Kauvar DS, Holcomb JB, Norris GC, Hess JR. Fresh whole blood transfusion: a controversial military practice. J Trauma. 2006;61:181–184.
64. Eastridge BJ, Jenkins D, Flaherty S, Schiller H, Holcomb JB. Trauma system development in a theater of war: experiences from Operation Iraqi Freedom and Operation Enduring Freedom. J Trauma. 2006;61:1366–1373.
© 2007 Lippincott Williams & Wilkins, Inc.